(Total Views: 521)
Posted On: 07/24/2024 12:30:40 AM
Post# of 148878
Agree 100%. Anything FDA approves ahead of any indication we target, is outstanding for Cytodyn.
I look @ Cytodyn as 20% / safety metric, for success.
If LL performs @ a minimum of that range % improvement, over whichever head to head drug or even LL Vs a combo trial.................
Then our safety will bring it home for the win.
Every single time.
......... Leronlimab becomes dominant.
( of course, even with efficacious being the same, is good enough...but I'm just trying to ( for now ) stay void of over excitement by creating a hypothetical % number )
: )
I look @ Cytodyn as 20% / safety metric, for success.
If LL performs @ a minimum of that range % improvement, over whichever head to head drug or even LL Vs a combo trial.................
Then our safety will bring it home for the win.
Every single time.
......... Leronlimab becomes dominant.
( of course, even with efficacious being the same, is good enough...but I'm just trying to ( for now ) stay void of over excitement by creating a hypothetical % number )
: )
(1)
(0)Scroll down for more posts ▼
